not used title

not used title

Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents encouraged the R&D that led to these innovations. Patents are a form of intellectual property protection that give inventors the exclusive right to make, use, sell, offer for sale or import their inventions for a set period of time. This alleviates some of the risk inventors take on when developing new products. Patients are well-served by having more inventions protected by intellectual property – it means more competition so more access to medicines in the long run – and these protections are an investment in the system that fosters innovation. Patents are not just handed out. The process for obtaining a patent is no small feat. It often takes about two years for an applicant to be granted a patent because the process requires an extensive and robust review by expert patent examiners at the United States Patent and Trademark Office (USPTO). 

From idea to application

Whether it’s a golf ball or a COVID-19 vaccine, innovation begins as an idea that can become an invention. An invention can then be the subject of a patent application formally filed with the USPTO. The patent application must describe the invention clearly enough for someone knowledgeable in the field to understand, make and use it. The patent application also breaks an invention down into discrete claims which become the legal description of the aspects of the invention that are protected by law. Typically, in the biopharmaceutical industry, a long period of research and development is carried out before companies even file for a patent. 

From application to evaluation

The application is then evaluated by a USPTO patent examiner – typically a skilled scientist or engineer – who thoroughly reviews the application to ensure the application meets the long-established legal requirements, including being novel, useful and nonobvious. More than 85% of patent applications are rejected at least once. If that happens, the applicant can try to address the examiner’s concerns by amending the written application, and in some cases, also through an on-the-record discussion with the examiner. Ultimately, the examiner must be satisfied before a patent will be allowed. Applicants can also appeal an examiner’s rejections if the applicant is unable to overcome the examiner’s rejections but does not believe the rejections have merit.

From application to issuance

The process from patent application to issuance takes about two years on average. Once a patent is granted, the inventor has the right to prevent others from making, using, selling, offering to sell or importing the patented invention for a basic period of 20 years from the application’s filing date. In the case of innovative medicines, a patent does not constitute authorization to sell a product made with the invention; that is determined by the U.S. Food and Drug Administration (FDA). Even after an innovator begins applying for patent protection for each innovation incorporated into a medicine, it still often must spend years in clinical trials proving the medicine’s safety and efficacy before it can bring the medicine to market. This means that the innovator does not typically enjoy the entire 20-year patent term for each innovation that makes a medicine possible.

Obtaining a patent is a rigorous and thorough process. Patents are an essential incentive to innovation and encourage companies to make the needed investments to develop new treatments and potential cures that are vitally important to patients. Patents are particularly important to the biopharmaceutical industry, as only 12% of new treatments that make it to clinical trials are ultimately approved by FDA for use. 

Learn more about the process for obtaining a patent here. 

Megan Van Etten

Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.

Megan Van Etten

The $1.74 trillion sector powering America’s economy

October 29, 2026

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

ICYMI: Biopharmaceutical companies in America hit new investment milestone

August 14, 2026

World Sickle Cell Day: Recognizing the promise of gene therapy

June 19, 2026

America's cancer research progress is real and worth protecting

May 28, 2026

Ahead of ASCO: Cancer innovation is promising, but policy choices matter

May 26, 2026

How AI is transforming the drug innovation lifecycle

March 19, 2026

Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs

February 2, 2026

How post-approval innovation keeps delivering for patients

December 9, 2025

What to know about vaccine ingredients: Aluminum and thimerosal

June 24, 2025

Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share

June 17, 2025

PhRMA Foundation celebrates 60 years of investing in future scientific leaders

June 11, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

4 things to know on Rare Disease Day

February 28, 2025

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report

February 21, 2025

New policy agenda charts solutions for a healthier America

February 20, 2025

A successful PhRMA Forum highlights our commitment to a healthier America

February 20, 2025

Guest Perspective: Prioritize Innovative Care

February 11, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

A new administration poses new opportunities for patient access

December 17, 2024

Congratulations to our 2024 Working for Cures Employee Champions

December 11, 2024

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.

November 13, 2024

New Report: Tackling chronic conditions with preventive treatment

September 30, 2024

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

September 24, 2024

40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?

September 23, 2024

Addressing the mounting threat of antimicrobial resistance

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Biden Administration report debunks myths around patent “evergreening” and “thickets”

September 3, 2024

How to protect your children’s health this school year

August 22, 2024

What to know about the latest effort to break patents using a legally dubious avenue

August 21, 2024

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation

August 12, 2024

Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers

August 1, 2024

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

New Report: Vaccines continue to drive improved health outcomes

July 16, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

Alzheimer's & Brain Awareness Month: A conversation with Biogen

June 27, 2024

PhRMA launches education campaign on the benefits of America's IP system

June 26, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eisai

June 24, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company

June 20, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

Women’s Health Month: A conversation with Astellas

May 31, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Experts discuss the value of IP at Senate Judiciary Committee hearing

May 28, 2024

Mental Health Awareness Month: Supporting loved ones and improving mental health in America

May 28, 2024

Women’s Health Month: A conversation with Sage

May 23, 2024

The use of real-world data in drug development

May 13, 2024

New analysis: Accelerated approval pathway is changing lives in underserved communities

April 30, 2024

World Vaccine Congress: Building on vaccine success

April 1, 2024

The impact of innovative medicines: A caregiver's perspective

March 26, 2024

ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development

March 25, 2024

What new cures would mean to families

March 7, 2024

Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day

February 29, 2024

American Heart Month: A nurse’s perspective

February 27, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

Three things to know about antibody drug conjugates

February 2, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high

January 23, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

The White House continues to attack American innovation

December 15, 2023

Taking stock of obesity and its costly effects

December 8, 2023

Congratulations to our 2023 Working for Cures Employee Champions

December 6, 2023

Watch: Putting patients front and center for World AIDS Day

November 30, 2023

Misuse of march-in could stifle innovation

November 27, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

Don't close the door on rare disease research

November 13, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

October 18, 2023

Three things economists are saying about the Inflation Reduction Act

October 11, 2023

Celebrating Hispanic Heritage Month at PhRMA

October 11, 2023

Word of the Month: AMR

September 27, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients

September 11, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

Decentralized clinical trials and the future of drug development

August 9, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

Biopharmaceutical science powered by PRIDE

June 16, 2023

ASCO 2023: Protecting our progress in the fight against cancer

June 15, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Highlights from ASCO 2023

June 8, 2023

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

May 11, 2023

Support for continued progress is critical for pediatric drug development

May 8, 2023

New resource underscores the importance of small molecule medicines

May 4, 2023

Policies need to address the growing threat of antimicrobial resistance

April 28, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

A guide to MedPAC’s Part B vote today

April 13, 2023

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability

April 7, 2023

New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans

March 28, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

IRA Impacts: Cancer treatment research and development

March 23, 2023

PhRMA submits comments to OSTP on enhancing clinical trial diversity

March 21, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

February 28, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

State policymakers can protect American innovation and help Americans live longer, healthier lives

February 9, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Six ways I-MAK is lying about biopharma patents

November 16, 2022

Congratulations to our 2022 Working for Cures Employee Champions

November 10, 2022

New government price setting policy threatens post-approval research

November 10, 2022

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

November 8, 2022

New paper: Addressing the growing crisis of mental health and substance use disorders

November 7, 2022

Protecting treatment advances for breast cancer

October 31, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

Mental Illness Awareness Week – A time for reflection

October 3, 2022

New report ignores benefits of patent system to innovation and patients

September 30, 2022

New Report: Nearly 800 medicines in development to treat chronic conditions

September 29, 2022

Recognizing National Sickle Cell Awareness Month

September 23, 2022

The dangers of expanding the TRIPS waiver

September 19, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

August 10, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

August 1, 2022

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

July 29, 2022

The Senate’s latest price setting proposal will undermine: American medical innovation

July 27, 2022

Patent policy changes proposed by USPTO and FDA would leave patients behind

July 22, 2022

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

July 18, 2022

Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

July 14, 2022

Word of the Month: Biomarkers and surrogate endpoints

July 11, 2022

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

July 7, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Key takeaways from ASCO's annual meeting

June 10, 2022

Biopharmaceutical researchers to discuss the value of R&D with Congress

June 9, 2022

Recognizing LGBTQ+ Pride in biopharmaceutical science

June 9, 2022

Report: More than 500 medicines in development to treat disorders of the blood

May 18, 2022

Ensuring timely reauthorization of PDUFA and BsUFA

May 11, 2022

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

May 9, 2022

Spotlighting a growing mental health challenge

May 9, 2022

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

April 28, 2022

The biopharmaceutical industry leads in helping women achieve new heights, according to IAM’s diversity 100

April 20, 2022

Report: More than 600 medicines in development for diseases affecting women

March 31, 2022

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

March 17, 2022

Biopharmaceutical industry drives economic growth in all 50 states

March 14, 2022

Biopharmaceutical research and development has ushered in a decade of innovation in rare disease

February 28, 2022

4 things to know about biopharmaceutical efforts to fight cancer

February 24, 2022

What you need to know about newly authorized COVID-19 antiviral treatments

February 22, 2022

Guest post: Joining forces to combat the COVID-19 mental health crisis

February 17, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

The importance of timely PDUFA and BsUFA reauthorization

February 3, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

Protecting U.S. innovation abroad to support economic and pandemic recovery

February 1, 2022

ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

January 26, 2022

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

January 24, 2022

New data show continued decline in death rates for cancer patients related to treatment advances

January 20, 2022

Legislation threatens patent protections and future innovation

January 12, 2022

New Report: Nearly 800 new medicines in development to treat rare diseases

December 16, 2021

Recap: Our inaugural graduate summit and career expo

December 8, 2021

New report details the promise of the biopharmaceutical pipeline

December 7, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS

December 1, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

November 18, 2021

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

November 1, 2021

Guest post: Continued research and development is critical for ALS patients and families

October 25, 2021

New report shows more than 260 medicines in development to fight neurodegenerative diseases

October 12, 2021

The important role of antivirals in the fight against COVID-19

October 6, 2021

Understanding Long COVID-19

September 29, 2021

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

September 28, 2021

Meeting Tomorrow: Looking ahead to PDUFA VII

September 27, 2021

PhRMA releases 2021 industry profile

September 20, 2021

Addressing data challenges to improve health equity

September 17, 2021

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

September 8, 2021

Patients and innovators lose if the government pursues ‘march-in’

September 7, 2021

The impact of monoclonal antibodies and COVID-19 recovery

September 2, 2021

Recognizing National Immunization Awareness Month

August 31, 2021

PDUFA VII is critical for future biopharmaceutical innovation and for patients

August 23, 2021

Recognizing Hepatitis R&D on World Hepatitis Day

July 28, 2021

We Work for Health: Discovering champions, even amid challenging times

July 26, 2021

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

July 22, 2021

3 things that support robust biopharmaceutical research and development

June 29, 2021

Watch: Building trust and enhancing clinical trial diversity

June 24, 2021

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

June 23, 2021

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

June 22, 2021

Researchers to shine light on biopharmaceutical R&D with policymakers

June 15, 2021

How research evolves and brings new hope to patients

June 11, 2021

Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

June 4, 2021

Creating a new patient risk paradigm in American health care

May 18, 2021

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

May 14, 2021

The Biden Administration allows politics to upend a pragmatic pandemic response

May 14, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

Reflecting on Mental Health Awareness Month

May 4, 2021